Among New Drug Launches, Oncology Scores Big While CV Lags
Executive Summary
Bristol’s Opdivo and Pfizer’s Ibrance are standouts among recent drug launches, well on their way to becoming commercial blockbusters, while new cardiovascular drugs like Repatha, Praluent and Entresto, forecast to become blockbusters in their own right, have been slow at launch, restrained by market access.